Rare
lephants
Screener
Toggle theme
Interpace Biosciences Inc
IDXG
·
Healthcare, Medical Devices, United States
Financial Statements
Profitability
Balance Sheet
Cash Flow
Share-Based Metrics
Valuation
Cash Flow History
Net Cash Flow Breakdown
Net Cash Flow
Cash Flow
›
Net Cash Flow Breakdown
Net Cash Flow Breakdown
Chart
Table
FY2025
FY2024
FY2023
FY2011
FY2010
Total Cash from Operations:
$25.0M
Line Item
Value
% of Total
Capital Expenditures
$356.0K
1.4%
Other Financing
$4.4M
17.7%
Working Capital
$19.2M
76.7%
Net Cash Flow
$1.0M
4.2%
Download CSV
